CytoDyn to Host R&D Update on Wednesday, December 7, 2022
22 nov. 2022 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
28 oct. 2022 17h15 HE
|
CytoDyn Inc.
Company to complete and submit responses to FDA clinical hold Continues to study leronlimab in other HIV-related, NASH, and oncology indications Webcast to be held Monday, October 31, 2022, at 5:30...
CytoDyn Announces Appointment of Additional Directors with Industry Experience
20 oct. 2022 08h30 HE
|
CytoDyn Inc.
Stephen Simes career public biotech company CEO and Ryan Dunlap CFO with public biotech company experience join Board VANCOUVER, Wash., Oct. 20, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY)...
CytoDyn to Hold Webcast to Provide a Quarterly Company Update
19 sept. 2022 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Sept. 19, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President
13 juil. 2022 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, July 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab
11 juil. 2022 08h30 HE
|
CytoDyn Inc.
$5 Million Grant Awarded to OHSU for Preclinical Research of One-time Injection of Gene Therapy Based on Leronlimab for Functional Cure of HIV VANCOUVER, Washington, July 11, 2022 (GLOBE...
CytoDyn to Hold Webcast to Provide a Quarterly Company Update
22 juin 2022 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, June 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer
23 mai 2022 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, May 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor
13 mai 2022 08h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, May 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species”
12 avr. 2022 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, April 12, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...